Cipla signs pact with Novartis Pharma AG for Galvus

Cipla on Monday said that it has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used in the treatment of type 2 diabetes from January 1, 2026.

The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus branded products. 

“This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” the company said in a stock exchange filing.

One of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space, especially in the oral diabetic medication category, Galvus has the potential to contribute significantly to its portfolio with reported sales of Rs268 crore, the pharma company said citing IQVIA (MAT February 2023) numbers.